Israel Englander funds hold over 5% of Tenax Therapeutics (TENX)

Rhea-AI Filing Summary

TENAX THERAPEUTICS, INC. (TENX) received a Schedule 13G reporting a significant ownership position by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These reporting persons disclose beneficial ownership of 2,156,891 shares of Tenax Therapeutics common stock, representing 5.8% of the outstanding class. They report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over the same 2,156,891 shares. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Mr. Englander. The filing states that this structure should not, by itself, be construed as an admission by any of the reporting persons of beneficial ownership of the securities held by those entities.

Key Figures

Shares beneficially owned: 2,156,891 shares Percent of class: 5.8% Shared voting power: 2,156,891 shares +3 more

6 metrics

Shares beneficially owned 2,156,891 shares Common stock of Tenax Therapeutics, Inc. reported by each reporting person

Percent of class 5.8% Percentage of Tenax Therapeutics common stock class beneficially owned

Shared voting power 2,156,891 shares Shares over which the reporting persons have shared power to vote or direct the vote

Shared dispositive power 2,156,891 shares Shares over which the reporting persons have shared power to dispose or direct disposition

CUSIP 88032L605 CUSIP for Tenax Therapeutics, Inc. common stock

Filing date of joint agreement August 17, 2026 Date of Joint Filing Agreement among the reporting persons

Key Terms

Schedule 13G, beneficially owned, shared voting power, shared dispositive power, +1 more

5 terms

Schedule 13G regulatory

"received a Schedule 13G reporting a significant ownership position"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 2,156,891.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 2,156,891.00"

dispositive power financial

"Sole power to dispose or to direct the disposition of"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

What percentage of TENX does Millennium Management report owning in this Schedule 13G?

Millennium Management and related reporting persons report beneficial ownership of 5.8% of Tenax Therapeutics (TENX) common stock, based on 2,156,891 shares. This ownership is reported on a shared voting and shared dispositive power basis.

How many TENX shares are reported as beneficially owned by Millennium on this Schedule 13G?

The reporting group discloses beneficial ownership of 2,156,891 shares of Tenax Therapeutics common stock. These shares carry shared voting power and shared dispositive power, with no sole voting or dispositive authority reported for any of the filers.

Who are the reporting persons on the TENX Schedule 13G filed in August 2026?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. They file jointly under a Joint Filing Agreement and report shared voting and dispositive power over 2,156,891 Tenax Therapeutics shares.

What voting power over TENX shares does Millennium report in this Schedule 13G?

The filers report 0 shares with sole voting power and 2,156,891 shares with shared voting power. They also report an identical 2,156,891 shares with shared dispositive power and no sole dispositive power over any Tenax Therapeutics shares.

Does the Schedule 13G state that Millennium admits beneficial ownership of TENX shares?

The filing states that it should not be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Israel A. Englander of the securities held by the underlying entities subject to their control.

Where are the main Millennium entities in the TENX Schedule 13G organized and based?

Millennium Management LLC and Millennium Group Management LLC are organized in Delaware, with principal offices at 399 Park Avenue, New York, New York 10022. Israel A. Englander is a citizen of the United States and is associated through Millennium Management LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 07:09 PM Accepted by SEC EDGAR 08/18/2026 - 07:08 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tenax Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

08/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,156,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,156,891.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,156,891.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,156,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,156,891.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,156,891.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,156,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,156,891.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,156,891.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tenax Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	08/17/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	08/17/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	08/17/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 17, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.